Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

York U researchers uncovering how ovarian cancer resists chemotherapy

03.03.2011
York University researchers have zeroed in on a genetic process that may allow ovarian cancer to resist chemotherapy.

Researchers in the university's Faculty of Science & Engineering studied a tiny strand of our genetic makeup known as a MicroRNA, involved in the regulation of gene expression. Cancer occurs when gene regulation goes haywire.

"Ovarian cancer is a very deadly disease because it's hard to detect," says biology professor Chun Peng, who co-authored the study. By the time it's diagnosed, usually it is in its late stages. And by that point there's really no way to treat the disease. Even when the disease is discovered in its early stages, chemotherapy doesn't always work," she says.

Peng was among a team of researchers that discovered a receptor, ALK7, that induces cell-death in epithelial ovarian cancer cells. They have now discerned that microRNA 376c targets this crucial receptor, inhibiting its expression and allowing ovarian cancer cells to thrive.

"Our evidence suggests that microRNA 376c is crucial to determining how a patient will respond to a chemotherapeutic agent," says Peng. "It allows cancer cells to survive by targeting the very process that kills them off," she says.

In examining tumours taken from patients who were non-responsive to chemotherapy, researchers found a higher expression of microRNA 376c and a much lower expression of ALK7.

Peng believes that this research is a step towards being able to make chemotherapy drugs more effective in the treatment of the disease.

"Further study is needed, but ultimately if we can introduce anti-microRNAs that would lower the level of those microRNAs that make cancer cells resistant to chemotherapeutic drugs, we will be able to make chemotherapy more effective against ovarian cancer," Peng says.

She urges women to educate themselves about the risk factors and symptoms of the disease. For more information, visit http://www.ovariancanada.org .

Peng is a world expert in the area of ovarian cancer and the molecular basis of complications in pregnancy. Her research on chemo-resistance has also contributed to knowledge and prediction of pre-eclampsia, a pregnancy disorder that is a leading cause of maternal and perinatal complications and death.

The article, "MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance," was published in the Journal of Cell Science.

The study's lead author, Gang Ye, is a Research Associate in Peng's lab. Several trainees in Peng's lab, as well as scientists in Toronto's Sunnybrook Research Institute and in China also participated in the project.

The research was supported by an operating grant from the Canadian Institutes of Health Research (CIHR) and a mid-career award to Peng from the Ontario Women's Health Council/CIHR. Ye was supported in part by a Fellowship from the Toronto Ovarian Cancer Research Network.

York University is the leading interdisciplinary research and teaching university in Canada. York offers a modern, academic experience at the undergraduate and graduate level in Toronto, Canada's most international city. The third largest university in the country, York is host to a dynamic academic community of 50,000 students and 7,000 faculty and staff, as well as 200,000 alumni worldwide. York's 10 Faculties and 28 research centres conduct ambitious, groundbreaking research that is interdisciplinary, cutting across traditional academic boundaries. This distinctive and collaborative approach is preparing students for the future and bringing fresh insights and solutions to real-world challenges. York University is an autonomous, not-for-profit corporation.

Media Contact:

Melissa Hughes, Media Relations, York University, 416 736 2100 x22097, mehughes@yorku.ca

Melissa Hughes | EurekAlert!
Further information:
http://www.yorku.ca

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>